Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
Moodys
Dow
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Talimogene laherparepvec

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Talimogene laherparepvec?

Talimogene laherparepvec is an investigational drug.

There have been 35 clinical trials for Talimogene laherparepvec. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2011.

The most common disease conditions in clinical trials are Melanoma, Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are Amgen, Merck Sharp & Dohme Corp., and BioVex Limited.

There are three US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for Talimogene laherparepvec
TitleSponsorPhase
Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi SarcomaAssistance Publique - Hôpitaux de ParisPhase 2
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)Merck Sharp & Dohme Corp.Phase 2
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)AmgenPhase 2

See all Talimogene laherparepvec clinical trials

Clinical Trial Summary for Talimogene laherparepvec

Top disease conditions for Talimogene laherparepvec
Top clinical trial sponsors for Talimogene laherparepvec

See all Talimogene laherparepvec clinical trials

US Patents for Talimogene laherparepvec

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Talimogene laherparepvec   Start Trial Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor Amgen Inc. (Thousand Oaks, CA)   Start Trial
Talimogene laherparepvec   Start Trial Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA)   Start Trial
Talimogene laherparepvec   Start Trial GITR antigen binding proteins and methods of use thereof AMGEN INC. (Thousand Oaks, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Talimogene laherparepvec

Drugname Country Document Number Estimated Expiration Related US Patent
Talimogene laherparepvec Australia 2013308595 2032-08-30   Start Trial
Talimogene laherparepvec Australia 2018208640 2032-08-30   Start Trial
Talimogene laherparepvec Canada 2881851 2032-08-30   Start Trial
Talimogene laherparepvec China 104704002 2032-08-30   Start Trial
Talimogene laherparepvec Eurasian Patent Organization 201590451 2032-08-30   Start Trial
Talimogene laherparepvec European Patent Office 2890714 2032-08-30   Start Trial
Talimogene laherparepvec European Patent Office 3381942 2032-08-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
AstraZeneca
Harvard Business School
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.